U.S. Cell And Gene Therapy CDMO Market (2025 - 2033) Size, Share & Trends Analysis Report By Phase (Pre-clinical, Clinical), By Product (Gene Therapy, Cell Therapy, Gene-Modified Cell Therapy), By Indication (Oncology, Infectious Diseases), And Segment Forecasts

Market Segmentation

U.S. Cell and Gene Therapy CDMO Phase Outlook (Revenue in USD Million, 2021 - 2033)
- Pre-clinical
- Clinical
U.S. Cell and Gene Therapy CDMO Product Outlook (Revenue in USD Million, 2021 - 2033)
- Gene Therapy
  - Ex-vivo
  - In-vivo
- Gene-Modified Cell Therapy
  - CAR T-cell therapies
  - CAR-NK cell therapy
  - TCR-T cell therapy
  - Other
- Cell Therapy
U.S. Cell and Gene Therapy CDMO Indication Outlook (Revenue in USD Million, 2021 - 2033)
- Oncology
- Infectious Diseases
- Neurological disorders
- Rare Diseases
- Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments